Growth hormone and glucose metabolism: the model of the GH-receptor - 12/10/17
Résumé |
Pegvisomant is a GH analogue that includes a single amino acid substitution at position 120 that generates the GHR antagonist. Additional changes include amino acid substitutions within binding site 1 and a further modification by the addition of polyethylene glycol moieties that increase the half-life and reduce the immunogenicity of the molecule. In acromegalics, pegvisomant is the most effective treatment for normalizing the IGF-I, and pegvisomant significantly improves insulin sensitivity in patients suffering from acromegaly. However, there are simply no data available that might support a role for pegvisomant treatment in disorders in which glucose metabolism is disturbed and in which reducing GH action would be theoretically beneficial.
Le texte complet de cet article est disponible en PDF.Key words : Growth hormone, pegvisomant, IGF-1, glucose
Plan
Vol 65 - N° 1
P. 81-83 - février 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.